Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique

Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable dr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2019-10, Vol.69 (10), p.1809-1811
Main Authors: Bastard, Mathieu, Molfino, Lucas, Mutaquiha, Cláudia, Galindo, Miriam Arago, Zindoga, Pereira, Vaz, Deise, Mahinça, Ivan, DuCros, Philipp, Rusch, Barbara, Telnov, Alex
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciz196